Media coverage about Galapagos NV (NASDAQ:GLPG) has been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Galapagos NV earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.4672932615962 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s analysis:
- Company In The Limelight: Galapagos NV (GLPG) - Danville Daily (danvilledaily.com)
- Is a Surprise Coming for Galapagos (GLPG) This Earnings Season? (finance.yahoo.com)
- Galapagos NV (GLPG) Ticking 0.74%, Holding Above Rising Trendline - FLBC News (flbcnews.com)
- Galapagos NV (NASDAQ:GLPG) Expected to Post FY2017 Earnings of ($2.23) Per Share (americanbankingnews.com)
- Epizyme, Inc. (EPZM) is stand at $11.40 While Galapagos NV (GLPG) valued at $79.35 per share - Stocks Gallery (stocksgallery.com)
Shares of Galapagos NV (NASDAQ GLPG) opened at 75.86 on Friday. Galapagos NV has a 12-month low of $51.91 and a 12-month high of $94.88. The stock’s market capitalization is $3.86 billion.
A number of research firms recently commented on GLPG. Stifel Nicolaus lifted their target price on shares of Galapagos NV from $65.00 to $83.00 and gave the stock a “hold” rating in a research note on Monday, May 1st. Janney Montgomery Scott cut shares of Galapagos NV from a “buy” rating to a “sell” rating in a research note on Monday, April 24th. TheStreet upgraded shares of Galapagos NV from a “d+” rating to a “c” rating in a research note on Wednesday, May 17th. Zacks Investment Research lowered shares of Galapagos NV from a “buy” rating to a “hold” rating in a report on Monday, April 24th. Finally, BTIG Research reaffirmed a “buy” rating and set a $98.00 target price on shares of Galapagos NV in a report on Tuesday, June 20th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $93.33.
About Galapagos NV
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.
